Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI), a leading developer of stem cell technologies, is committed to providing treatments for neurodegenerative diseases that are currently incurable. The company’s focus is on developing NTF cells from the patient’s own bone marrow to treat, Parkinson, ALS, and Spinal Cord Injury. The Brainstorm management and scientific teams are devoted to the company’s mission to regenerate the mind in their lifetime. For further information, visit the Company’s web site at www.brainstorm-cell.com.
- 17 years ago
QualityStocks
Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Profit Momentum Builds for Beeline Holdings Inc. (NASDAQ: BLNE) as Next-Gen Platform Accelerates
Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform redefining the path to homeownership, recently…
-
QualityStocksNewsBreaks – Why SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Is ‘One to Watch’
Disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB:…
-
QualityStocksNewsBreaks – BCII Enterprises Inc. (OTCID: BCII) Details Real-World Applications for Patent-Pending Coupon Token Architecture
BCII Enterprises (OTCID:BCII) today announced real-world applications for its patent-pending Coupon Token architecture, as detailed…